Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Operating Leases: 2019-2025

Historic Operating Leases for ImmunityBio (IBRX) over the last 7 years, with Sep 2025 value amounting to $41.4 million.

  • ImmunityBio's Operating Leases fell 5.36% to $41.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.4 million, marking a year-over-year decrease of 5.36%. This contributed to the annual value of $34.8 million for FY2024, which is 23.04% down from last year.
  • ImmunityBio's Operating Leases amounted to $41.4 million in Q3 2025, which was down 4.13% from $43.2 million recorded in Q2 2025.
  • ImmunityBio's Operating Leases' 5-year high stood at $52.1 million during Q2 2022, with a 5-year trough of $16.6 million in Q1 2021.
  • Over the past 3 years, ImmunityBio's median Operating Leases value was $43.8 million (recorded in 2023), while the average stood at $43.6 million.
  • Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 235.24% in 2021, then declined by 23.04% in 2024.
  • Quarterly analysis of 5 years shows ImmunityBio's Operating Leases stood at $40.1 million in 2021, then grew by 26.60% to $50.7 million in 2022, then dropped by 10.82% to $45.2 million in 2023, then declined by 23.04% to $34.8 million in 2024, then declined by 5.36% to $41.4 million in 2025.
  • Its Operating Leases was $41.4 million in Q3 2025, compared to $43.2 million in Q2 2025 and $40.6 million in Q1 2025.